Brief: Nxera Pharma Says Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases
02/06/2025 24:31
June 1 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA ACHIEVES DEVELOPMENT MILESTONE IN COLLABORATION WITH ELI LILLY TARGETING METABOLIC DISEASES NXERA PHARMA -EXPECTS TO RECEIVE MILESTONE PAYMENT IN Q3 OF FISCAL YEAR ENDING DECEMBER 2025 Source text: ID:nGNX2fFcv0 Further company coverage: 4565.T ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up